Literature DB >> 15982567

Induction of transplantation tolerance-the potential of regulatory T cells.

Ahmed Akl1, Shiqiao Luo, Kathryn J Wood.   

Abstract

Solid organ transplantation is widely accepted as an effective treatment for end organ failure. Although the treatment with immunosuppressive drugs has undoubtedly greatly improved graft survival, chronic rejection still has considerable impact on long term outcome. This, together with the undesirable side effects associated with life long treatment with immunosuppressive drugs, have significant implications for long term outcomes. In a small number of patients, drug non-compliance as well as controlled reduction or removal of maintenance immune suppressive drug therapy has led to the uncovering of a tolerant state. The challenge of achieving improved monitoring of all transplant patients may allow tailoring of immunosupression in a proportion of recipients thereby increasing the opportunities for the induction of specific unresponsiveness to donor alloantigens in the future. The immune system using several mechanisms to both induce and maintain tolerance to alloantigens, including the deletion of allo-reactive T cells, the induction of anergy, clonal exhaustion, ignorance and active suppression (immunoregulation) of allo-responses. A minor subpopulation of CD4+ T cells, regulatory or suppressor CD4+ T cells that co-express the cell-surface molecule CD25 (IL2 alpha subunit) at a high level may play a major role in the maintenance of specific unresponsiveness and operational tolerance to donor antigens in vivo. Intensive investigation of these cells in recent years has started to uncover the mechanisms of active suppression by regulatory T cells in this setting.

Entities:  

Mesh:

Year:  2005        PMID: 15982567     DOI: 10.1016/j.trim.2005.03.011

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  7 in total

1.  The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins.

Authors:  V D K D Sewgobind; L J W van der Laan; M M L Kho; R Kraaijeveld; S S Korevaar; W Mol; W Weimar; C C Baan
Journal:  Clin Exp Immunol       Date:  2010-05-28       Impact factor: 4.330

2.  Transplant tolerance: bench to bedside--26th annual Samuel Jason Mixter Lecture.

Authors:  David H Sachs
Journal:  Arch Surg       Date:  2011-05

3.  Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model.

Authors:  A Mario Marcondes; Xiang Li; Laura Tabellini; Matthias Bartenstein; Julia Kabacka; George E Sale; John A Hansen; Charles A Dinarello; H Joachim Deeg
Journal:  Blood       Date:  2011-09-06       Impact factor: 22.113

4.  Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells.

Authors:  Xunrong Luo; Kristin V Tarbell; Hua Yang; Kathryn Pothoven; Samantha L Bailey; Ruchuang Ding; Ralph M Steinman; Manikkam Suthanthiran
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-16       Impact factor: 11.205

5.  Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism.

Authors:  Kenneth D Bishop; John E Harris; John P Mordes; Dale L Greiner; Aldo A Rossini; Michael P Czech; Nancy E Phillips
Journal:  Cell Immunol       Date:  2009-02-23       Impact factor: 4.868

6.  alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice.

Authors:  Eli C Lewis; Mark Mizrahi; Michel Toledano; Nathaniel Defelice; Joanne L Wright; Andrew Churg; Leland Shapiro; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

7.  α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.

Authors:  A Mario Marcondes; Ekapun Karoopongse; Marina Lesnikova; Daciana Margineantu; Tobias Welte; Charles A Dinarello; David Hockenbery; Sabina Janciauskiene; H Joachim Deeg
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.